Repurposing non-oncology drugs with MET inhibitory effect to overcome osimertinib resistance in lung cancer

被引：0
|
作者：
To, Kenneth K. W.
Leung, Kwong Sak
Cho, William C. S.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7195
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] New use of Old Drugs: Repurposing of Non-oncology Drugs for Cancer and Oncology Drugs for other Human Diseases
    Das, Viswanath
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (10) : 1103 - 1103
  • [2] In vitro, in silico and in vivo screening of non-oncology drugs for repurposing in osteosarcoma
    Desai, Sujit
    Manjappa, Arehalli
    Khulbe, Preeti
    Choudhar, Prafulla
    Kumbhar, Popat
    JOURNAL OF RESEARCH IN PHARMACY, 2023, 27 (02): : 712 - 721
  • [3] Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
    Mohi-ud-din, Roohi
    Chawla, Apporva
    Sharma, Pooja
    Mir, Prince Ahad
    Potoo, Faheem Hyder
    Reiner, Zeljko
    Reiner, Ivan
    Atessahin, Dilek Arslan
    Sharifi-Rad, Javad
    Mir, Reyaz Hassan
    Calina, Daniela
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [4] Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
    Roohi Mohi-ud-din
    Apporva Chawla
    Pooja Sharma
    Prince Ahad Mir
    Faheem Hyder Potoo
    Željko Reiner
    Ivan Reiner
    Dilek Arslan Ateşşahin
    Javad Sharifi-Rad
    Reyaz Hassan Mir
    Daniela Calina
    European Journal of Medical Research, 28
  • [5] Uncovering non-oncology drugs that kill cancer cells
    Nguyen, Tien
    CHEMICAL & ENGINEERING NEWS, 2020, 98 (04) : 4 - 4
  • [6] Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions
    Fu, Leilei
    Jin, Wenke
    Zhang, Jiahui
    Zhu, Lingjuan
    Lu, Jia
    Zhen, Yongqi
    Zhang, Lan
    Ouyang, Liang
    Liu, Bo
    Yu, Haiyang
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (02) : 532 - 557
  • [7] Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions
    Leilei Fu
    Wenke Jin
    Jiahui Zhang
    Lingjuan Zhu
    Jia Lu
    Yongqi Zhen
    Lan Zhang
    Liang Ouyang
    Bo Liu
    Haiyang Yu
    Acta Pharmaceutica Sinica B, 2022, 12 (02) : 532 - 557
  • [8] The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer
    Waissengrin, B.
    Zahavi, T.
    Salmon-Divon, M.
    Goldberg, A.
    Wolf, I
    Rubinek, T.
    Winkler, T.
    Farkash, O.
    Grinshpun, A.
    Zubkov, A.
    Khatib, M.
    Shachar, S. S.
    Keren, N.
    Carmi-Levy, I
    Ben-David, U.
    Sonnenblick, A.
    ESMO OPEN, 2022, 7 (06)
  • [9] The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
    Waissengrin, Barliz
    Wolf, Ido
    Zahavi, Tamar
    Salmon-Divon, Mali
    Sonnenblick, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
    Codony-Servat, J.
    Codony-Servat, C.
    Viteri, S.
    Ito, M.
    Chaib, I.
    Bracht, J.
    Molina-Vila, M. A.
    Karachaliou, N.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2019, 30
12345